Plus Therapeutics director exercises 922 RSUs

PLUS THERAPEUTICS director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs), which were converted into an equal number of shares of Common Stock at a price of $0.00 per share.

Rhea-AI Filing Summary

PLUS THERAPEUTICS director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs), which were converted into an equal number of shares of Common Stock at a price of $0.00 per share. Following this transaction, the reporting person directly holds 922 shares of Common Stock.

The RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, meaning this filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale, with no shares disposed of in the transaction.

Insider Trade Summary

922 shares exercised/converted

Exercise 2 txns

Insider van Es-Johansson An

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	922	$0.00	$0.00
Exercise	Common Stock	922	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 2,764 contracts (Direct); Common Stock — 922 shares (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
2. F2. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.

Key Figures

Shares acquired: 922 shares Post-transaction holdings: 922 shares RSUs outstanding: 2,764 units +2 more

5 metrics

Shares acquired 922 shares Common Stock received from RSU conversion on July 1, 2026

Post-transaction holdings 922 shares Common Stock directly held after RSU vesting

RSUs outstanding 2,764 units Restricted Stock Units remaining after this derivative transaction

Vesting installments Four installments RSU grant vests in four substantially equal quarterly installments

Exercise price $0.00 per share Conversion of RSUs into Common Stock

Key Terms

Restricted Stock Unit, RSU, derivative security

3 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PLUS THERAPEUTICS (PSTV) report on this Form 4?

PLUS THERAPEUTICS reported that director An van Es-Johansson had 922 RSUs vest and convert into 922 Common Stock shares at $0.00 per share. The event is a compensation-related derivative exercise, not an open-market trade, and no shares were sold or disposed.

How many PLUS THERAPEUTICS (PSTV) shares does the director hold after this transaction?

After the transaction, the director directly holds 922 shares of PLUS THERAPEUTICS Common Stock. These shares resulted from the vesting and conversion of 922 Restricted Stock Units, as disclosed in the Form 4, with no accompanying open-market sales or dispositions reported.

What are the terms of the RSU vesting for PLUS THERAPEUTICS (PSTV) director An van Es-Johansson?

The RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026. This Form 4 reflects one such installment, where 922 RSUs vested and converted into 922 shares of Common Stock as part of the director’s equity compensation.

Did the PLUS THERAPEUTICS (PSTV) director buy or sell shares in the market in this Form 4?

No open-market buys or sells were reported. The Form 4 shows a derivative exercise where 922 RSUs converted into 922 Common Stock shares at $0.00 per share, reflecting equity compensation vesting rather than a discretionary market transaction.

How is the RSU-to-share relationship described for PLUS THERAPEUTICS (PSTV) in this filing?

Each Restricted Stock Unit represents a contingent right to receive one share of PLUS THERAPEUTICS Common Stock. In this transaction, 922 RSUs vested and were settled into 922 shares, consistent with the one-for-one RSU-to-share structure disclosed in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van Es-Johansson An

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		M		922(2)	A	$0(1)	922	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	07/01/2026		M			922	(2)	(2)	Common Stock	922	$0	2,764	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.

	Andrew Sims, as attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)